CIG directors lead world’s first ovarian cancer vaccine trial

Three directors from two of CICATS’ Core Interest Groups:  Women’s Cancer Consortium Core Interest Group (CIG) and the Personalized Immunotherapy CIG: Dr. Pramod Srivastava, Dr. Susan Tannenbaum, and Dr. Molly Brewer, are part of the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. Recruitment for the trial, which will take place at UConn Health, has begun and will be led by Dr. Tannenbaum. Dr. Srivastava, who is the director of the Neag Comprehensive Cancer Center at UConn Health, invented the groundbreaking vaccine, and Dr. Brewer and Karen Metersky, APRN, will serve as co-investigators.

To read more about this exciting announcement, check out the original article on UConn Today.

Update: Additional coverage includes a cover story from the May 8 edition of the Hartford Business Journal


This entry was posted in News.